Overview

A Study to Evaluate Efficacy and Safety of BGM1812 Injection in Overweight or Obese Participants Without Diabetes

Status:
NOT_YET_RECRUITING

Trial end date:
2027-08-01

Target enrollment:

Participant gender:

Summary

To evaluate the efficacy of BGM1812 injection compared with placebo in reducing body weight in overweight or obese participants without diabetes after 26 weeks of treatment.

Phase:

PHASE2

Details

Lead Sponsor:

BrightGene Bio-Medical Technology Co., Ltd.